<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of pulmonary disease in people who inject drugs</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of pulmonary disease in people who inject drugs</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of pulmonary disease in people who inject drugs</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joyce S Lee, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>People who inject drugs (PWID) are at increased risk for acute and chronic pulmonary complications. These sequelae may be due to pharmacodynamic properties of the drugs, effects of intravenous contaminants, or complications of the intravenous route of administration.</p><p>The general pulmonary complications and drug-specific pulmonary diseases that may result from injection drug use will be reviewed here. Other complications of injection drug use, such as foreign body granulomatosis, infective endocarditis, opioid use disorder, cocaine intoxication, and methamphetamine intoxication, are reviewed separately. (See  <a class="medical medical_review" href="/d/html/7807.html" rel="external">"Substance use disorders: Clinical assessment"</a> and  <a class="medical medical_review" href="/d/html/4370.html" rel="external">"Foreign body granulomatosis"</a> and  <a class="medical medical_review" href="/d/html/2149.html" rel="external">"Right-sided native valve infective endocarditis"</a> and  <a class="medical medical_review" href="/d/html/7803.html" rel="external">"Opioid use disorder: Pharmacologic management"</a> and  <a class="medical medical_review" href="/d/html/300.html" rel="external">"Acute opioid intoxication in adults"</a> and  <a class="medical medical_review" href="/d/html/303.html" rel="external">"Cocaine: Acute intoxication"</a> and  <a class="medical medical_review" href="/d/html/311.html" rel="external">"Methamphetamine: Acute intoxication"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">PULMONARY COMPLICATIONS</span><span class="headingEndMark"> — </span>The pulmonary complications associated with intravenous injection of illicit drugs include pneumonia, septic embolization, noncardiogenic pulmonary edema, foreign body granulomatosis, emphysema, interstitial lung disease, pulmonary vascular disease, pneumothorax, and an increased incidence of fatal asthma [<a href="#rid1">1-4</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Pneumonia</span><span class="headingEndMark"> — </span>PWID have a <strong>10-fold</strong> increased risk of community-acquired pneumonia compared with the general population [<a href="#rid2">2</a>]. This may be due to a number of factors:</p><p class="bulletIndent1"><span class="glyph">●</span>Concurrent smoking of cigarettes or illicit drugs may impair local lung defenses, macrophage activity, and mucociliary clearance</p><p class="bulletIndent1"><span class="glyph">●</span>The stupor induced by some injected drugs favors development of aspiration pneumonia or lung abscess (see  <a class="medical medical_review" href="/d/html/7024.html" rel="external">"Aspiration pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/7030.html" rel="external">"Lung abscess in adults"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Bacteremia may follow injection and may hematogenously infect the lung</p><p class="bulletIndent1"><span class="glyph">●</span>HIV-positive PWID are at substantially higher risk for bacterial pneumonia than HIV-negative PWID</p><p></p><p>The organisms that most commonly cause community-acquired pneumonia in this population include <em>Streptococcus pneumoniae</em>, <em>Staphylococcus aureus</em>, <em>Haemophilus influenzae</em>, <em>Klebsiella pneumoniae</em>, and <em>Escherichia coli</em>, although it is difficult to separate out the pathogens associated with HIV-positive and HIV-negative injection drug use [<a href="#rid5">5,6</a>]. Antimicrobial therapy is initially empiric and based on the clinical situation, particularly whether the chest radiograph shows focal or diffuse opacities and whether the patient meets criteria for hospital admission. In patients presenting with typical symptoms of bacterial pneumonia with focal consolidation on chest radiograph, the initial antibiotic regimen will be directed at the most common community-acquired pathogens. (See  <a class="medical medical_review" href="/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/3716.html" rel="external">"Bacterial pulmonary infections in patients with HIV"</a> and  <a class="medical medical_review" href="/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a> and  <a class="medical medical_review" href="/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a>.)</p><p>If the etiology of community-acquired pneumonia is identified using reliable microbiologic methods, antimicrobial therapy can be focused on that pathogen  (<a class="graphic graphic_table graphicRef64816" href="/d/graphic/64816.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Initial empiric therapy'</a>.)</p><p>For patients who have progressive disease despite antibiotic therapy for bacterial pneumonia, other considerations include fungal and mycobacterial agents. Candida pneumonia has been reported in PWID when the injection drug is contaminated [<a href="#rid2">2</a>].</p><p>Tuberculosis (particularly multidrug-resistant tuberculosis) is more prevalent among PWID than it is in the general population [<a href="#rid7">7-9</a>]. The excess risk largely relates to covariates which are more frequent among PWID, such as poverty, homelessness, malnutrition, HIV infection, and poor medical care. Tuberculosis should be suspected in patients with a longer prodrome, particularly in the presence of fever or night sweats for more than a week prior to presentation, or weight loss. In addition, mycobacterial disease should be suspected in patients with nonresolving pneumonia. (See  <a class="medical medical_review" href="/d/html/8018.html" rel="external">"Epidemiology of tuberculosis"</a> and  <a class="medical medical_review" href="/d/html/7026.html" rel="external">"Pulmonary tuberculosis: Clinical manifestations and complications"</a> and  <a class="medical medical_review" href="/d/html/6992.html" rel="external">"Nonresolving pneumonia", section on 'Tuberculosis'</a>.)</p><p>The use of injection drugs is a strong risk factor for the acquisition of HIV infection. PWID who present with pneumonia should be assessed for possible HIV infection. In the presence of known HIV infection, a variety of opportunistic pulmonary infections in addition to tuberculosis may occur. (See  <a class="medical medical_review" href="/d/html/3721.html" rel="external">"Evaluation of pulmonary symptoms in persons with HIV"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Septic emboli</span><span class="headingEndMark"> — </span>Septic pulmonary emboli can originate in the peripheral veins at sites of thrombophlebitis or they can arise from heart valves that have been damaged and infected due to injection drug use. Right-sided valve (tricuspid) endocarditis is generally found to be more common among PWID than left-sided. (See  <a class="medical medical_review" href="/d/html/2140.html" rel="external">"Pathogenesis of vegetation formation in infective endocarditis"</a> and  <a class="medical medical_review" href="/d/html/2149.html" rel="external">"Right-sided native valve infective endocarditis", section on 'Clinical manifestations'</a>.)</p><p>Patients typically present with fever, but generally do not have an audible murmur or peripheral stigmata of infective endocarditis. Blood cultures are usually positive. The radiographic manifestations of septic pulmonary emboli include ill-defined, nodular pulmonary opacities, cavities, abscesses, infarction, and pulmonary gangrene  (<a class="graphic graphic_diagnosticimage graphicRef59037" href="/d/graphic/59037.html" rel="external">image 1</a>). The evaluation and treatment of infective endocarditis in PWID is discussed separately. (See  <a class="medical medical_review" href="/d/html/2149.html" rel="external">"Right-sided native valve infective endocarditis"</a>.)</p><p class="headingAnchor" id="H87979163"><span class="h2">Noncardiogenic pulmonary edema</span><span class="headingEndMark"> — </span>Noncardiogenic pulmonary edema (NPE) refers to the radiographic evidence of alveolar fluid accumulation without hemodynamic evidence to suggest a cardiogenic etiology and is caused by increased pulmonary capillary permeability. NPE can occur following intravenous injection of cocaine and, more commonly, opioids [<a href="#rid3">3,10-12</a>]. Acute respiratory distress syndrome (ARDS) is a more severe form of NPE, associated with severe hypoxemia and the need for mechanical ventilatory support. (See  <a class="medical medical_review" href="/d/html/3456.html" rel="external">"Noncardiogenic pulmonary edema"</a> and  <a class="medical medical_review" href="/d/html/1609.html" rel="external">"Acute respiratory distress syndrome: Epidemiology, pathophysiology, pathology, and etiology in adults", section on 'Etiologies and predisposing factors'</a>.)</p><p>The exact pathophysiology of NPE due to opioid overdose (eg, heroin or <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>) is unknown, but may include a direct effect of the drug, cerebral edema (neurogenic), or possibly negative pressure. Patients with central nervous system depression due to a drug overdose can develop upper airway obstruction. Breathing against the obstruction can create a strong negative pressure across the alveoli, which causes pulmonary capillary leakage. (See  <a class="medical medical_review" href="/d/html/3456.html" rel="external">"Noncardiogenic pulmonary edema", section on 'Opioid overdose'</a> and  <a class="medical medical_review" href="/d/html/3456.html" rel="external">"Noncardiogenic pulmonary edema", section on 'Neurogenic pulmonary edema'</a>.)</p><p>Patients typically present with decreased mental status and evidence of respiratory insufficiency (eg, tachypnea, tachycardia, hypoxemia). Patients with NPE due to opiate intoxication typically have severe respiratory depression requiring <a class="drug drug_general" data-topicid="9678" href="/d/drug information/9678.html" rel="external">naloxone</a> reversal. Co-intoxication with alcohol or cocaine is present in approximately 50 percent [<a href="#rid11">11</a>]. The majority of these patients are hypoxemic on arrival in the emergency department [<a href="#rid10">10,11</a>].</p><p>Imaging findings in PWID with NPE were described in a series of 27 patients with opiate-related NPE: 74 percent had bilateral, ground-glass opacities suggestive of pulmonary edema, while unilateral pulmonary edema or focal opacities were noted in the remainder [<a href="#rid10">10</a>].</p><p>The diagnosis of NPE in PWID is based on the clinical presentation and exclusion of processes in the differential diagnosis, which includes the other causes of ARDS that may complicate injection drug use, such as sepsis, pneumonia (bacterial, viral, fungal), aspiration, cardiogenic pulmonary edema, and pulmonary embolism. (See  <a class="medical medical_review" href="/d/html/3456.html" rel="external">"Noncardiogenic pulmonary edema"</a>.)</p><p>For most PWID with NPE, treatment is supportive. Symptoms and signs typically resolve in 24 hours with supportive care (eg, supplemental oxygen), although approximately one-third of patients require mechanical ventilation for 24 to 48 hours. (See  <a class="medical medical_review" href="/d/html/300.html" rel="external">"Acute opioid intoxication in adults"</a> and  <a class="medical medical_review" href="/d/html/3456.html" rel="external">"Noncardiogenic pulmonary edema", section on 'Treatment'</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Foreign body granulomatosis</span><span class="headingEndMark"> — </span>Drug users sometimes pulverize tablets intended for oral use, dissolve them in water, and inject them intravenously. Talc, starch, cotton, and cellulose are used as filler agents in these tablets and may be carried by the bloodstream until they lodge in the pulmonary capillary bed; chronic inflammation and multiple foreign body granulomas in the lungs may ensue.</p><p>Patients may be asymptomatic or may present with nonspecific complaints such as dyspnea, cough, or an increase in sputum production. Computed tomography (CT) typically shows diffuse, small nodules (2 to 3 mm) or ground-glass opacities  (<a class="graphic graphic_diagnosticimage graphicRef53000" href="/d/graphic/53000.html" rel="external">image 2</a>). Pulmonary hypertension, emphysema, and interstitial fibrosis can occur if the process is severe. The diagnosis and management of foreign body granulomatosis are discussed separately. (See  <a class="medical medical_review" href="/d/html/4370.html" rel="external">"Foreign body granulomatosis"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Bullous lung disease and emphysema</span><span class="headingEndMark"> — </span>Emphysema and bullous lung disease have been described in association with HIV infection, but HIV-negative PWID can also develop these complications, particularly when <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a>, or talc-containing drugs are injected [<a href="#rid13">13-15</a>]. (See  <a class="medical medical_review" href="/d/html/4370.html" rel="external">"Foreign body granulomatosis"</a>.)</p><p>In one series, the prevalence of bullous lung damage and emphysema among intravenous drug users (as assessed by chest radiographs) was 2 percent [<a href="#rid16">16</a>]. The bullous cysts were noted predominantly in the upper lobes and in the lung periphery, with sparing of the central portions of the lungs [<a href="#rid16">16,17</a>]. Other reports of patients who injected talc-containing drugs have reported a predominance of bullous changes in the lower lobes [<a href="#rid18">18,19</a>]. Patients present with cough and dyspnea, and usually have combined obstructive and restrictive defects on pulmonary function testing.</p><p>A separate cross-sectional study of 516 participants who injected drugs demonstrated an overall prevalence of obstructive lung disease (OLD) of 18.2 percent, as determined by spirometry [<a href="#rid20">20</a>]. Very few reported a prior diagnosis of emphysema (10.6 percent) despite a high prevalence of respiratory symptoms (44.7 percent). After adjustment for age, pack-years smoked, and Black race, injection drug use was associated with a 13 percent (95% CI 1-27) increased odds of OLD for every five years of injection drug use.</p><p class="headingAnchor" id="H7"><span class="h2">Interstitial lung disease</span><span class="headingEndMark"> — </span>Interstitial lung disease in PWID is generally associated with foreign body granulomatosis, but may also be a nonspecific finding due to previous episodes of infection, aspiration, or infarction. Lymphocytic interstitial pneumonia, a rare interstitial lung disease in the general population, is seen with increased frequency in HIV-infected individuals. In addition, organizing pneumonia, sarcoidosis, drug hypersensitivity, and immune reconstitution syndrome can develop in HIV-infected patients. (See  <a class="medical medical_review" href="/d/html/4370.html" rel="external">"Foreign body granulomatosis"</a> and  <a class="medical medical_review" href="/d/html/4310.html" rel="external">"Approach to the adult with interstitial lung disease: Clinical evaluation"</a> and  <a class="medical medical_review" href="/d/html/4358.html" rel="external">"Approach to the adult with interstitial lung disease: Diagnostic testing"</a> and  <a class="medical medical_review" href="/d/html/3721.html" rel="external">"Evaluation of pulmonary symptoms in persons with HIV", section on 'Causes of pulmonary disease in persons with HIV'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Pulmonary hypertension</span><span class="headingEndMark"> — </span>Pulmonary hypertension may be induced by obstruction or obliteration of the pulmonary vascular bed from multiple causes, including foreign body granulomatosis, emphysema, or interstitial disease. Patients who are HIV-positive may develop pulmonary arterial hypertension (PAH) with plexiform lesions and medial hypertrophy. The evaluation and management of pulmonary hypertension associated with HIV infection is discussed separately. (See  <a class="medical medical_review" href="/d/html/8246.html" rel="external">"Pulmonary arterial hypertension associated with human immunodeficiency virus"</a> and  <a class="medical medical_review" href="/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"</a>.)</p><p>Drugs with sympathomimetic properties (eg, cocaine, methamphetamine) can produce transient pulmonary vasoconstriction. It also appears that chronic use of these drugs can lead to irreversible injury and production of a syndrome indistinguishable from primary pulmonary hypertension. In one retrospective study, patients with idiopathic PAH were ten times more likely to use stimulants (ie, amphetamines, methamphetamines, or cocaine) than patients with PAH due to known risk factors, such as collagen vascular disease, congenital heart disease, or anorexigen use [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/8247.html" rel="external">"The epidemiology and pathogenesis of pulmonary arterial hypertension (Group 1)", section on 'Drugs and toxins'</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Pneumothorax and pneumomediastinum</span><span class="headingEndMark"> — </span>Pneumothorax may result from unsuccessful attempts to inject drugs into the central circulation via the subclavian and jugular veins ("pocket shots"). It has also been reported as a complication of crack cocaine use, septic pulmonary emboli, and drug-related bullous disease [<a href="#rid22">22,23</a>]. (See <a class="local">'Cocaine'</a> below.)</p><p>Pneumomediastinum is associated with inhalation of crack cocaine and, less commonly, intranasal cocaine [<a href="#rid24">24</a>]. It is most likely due to performance of a Valsalva maneuver after inhalation, rather than an effect of the drug. Approximately 20 percent also had a pneumothorax. (See  <a class="medical medical_review" href="/d/html/4343.html" rel="external">"Pulmonary complications of cocaine use", section on 'Pneumothorax and pneumomediastinum'</a>.)</p><p class="headingAnchor" id="H10"><span class="h2">Asthma</span><span class="headingEndMark"> — </span>PWID with asthma appear to have an increased risk of fatal asthma [<a href="#rid25">25-28</a>] (see  <a class="medical medical_review" href="/d/html/565.html" rel="external">"Identifying patients at risk for fatal asthma", section on 'Minor risk factors'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>One toxicologic study of 92 cases of fatal asthma in Chicago found evidence of substance abuse, most commonly cocaine or opiates, in 32 percent of individuals [<a href="#rid25">25</a>]. It is unclear whether the drugs themselves or other unidentified factors are responsible for the increased asthma fatalities. Optimal use of asthma medicines is less frequent among drug users [<a href="#rid26">26</a>], and antiinflammatory medications were being utilized by just two patients in the Chicago series.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective review of 152 urban asthma patients found that intubation and mechanical ventilation were required more often among patients presenting with an acute exacerbation if they use cocaine (31 versus 11.5 percent) or heroin (17 versus 2.3 percent), compared with nonusers [<a href="#rid27">27</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Amyloidosis</span><span class="headingEndMark"> — </span>Bilateral pulmonary nodules containing amyloid (AA) protein have been reported in PWID with HIV disease [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/d/html/8036.html" rel="external">"HIV infection and malignancy: Management considerations", section on 'Plasma cell disorders'</a>.)</p><p class="headingAnchor" id="H12"><span class="h1">DRUG-SPECIFIC COMPLICATIONS</span></p><p class="headingAnchor" id="H13"><span class="h2">Cocaine</span><span class="headingEndMark"> — </span>Cocaine is an alkaloid with anesthetic and central nervous system stimulant properties. It can be inhaled nasally or injected; a heat-stable form produced by boiling with bicarbonate can be smoked (“free-basing”). There is a higher incidence of clinically apparent pulmonary complications when cocaine is smoked versus used intravenously or intranasally. The pulmonary complications associated with the use of cocaine are multiple and can be divided into acute and chronic pulmonary disorders.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute pulmonary complications</strong> – The acute complications of injection cocaine use overlap with those of inhaled crack cocaine; the most common are acute pulmonary edema and pulmonary hemorrhage.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Acute noncardiogenic pulmonary edema (NPE) presents with the rapid onset of dyspnea, hypoxemia, and diffuse opacities on chest radiograph; altered mental status is frequently also present in PWID. Treatment is supportive and includes supplemental oxygen and ventilator support, if necessary. Clinical improvement generally occurs within 24 to 48 hours. (See <a class="local">'Noncardiogenic pulmonary edema'</a> above and  <a class="medical medical_review" href="/d/html/3456.html" rel="external">"Noncardiogenic pulmonary edema"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulmonary hemorrhage can occur with or without frank hemoptysis and is commonly found on autopsy in asymptomatic cocaine users [<a href="#rid30">30</a>]. The causes of hemorrhage are probably multifactorial and may include NPE, pulmonary infarction, infection, and pulmonary hypertension. Treatment is supportive. (See  <a class="medical medical_review" href="/d/html/4343.html" rel="external">"Pulmonary complications of cocaine use"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cardiogenic edema may result from cocaine-induced coronary artery spasm, myocardial ischemia, and left ventricular dysfunction  (<a class="graphic graphic_diagnosticimage graphicRef58394" href="/d/graphic/58394.html" rel="external">image 3</a>). The diagnosis is suspected in patients with dyspnea, diffuse pulmonary opacities on chest imaging, an elevated brain natriuretic peptide, and/or reduced left ventricular function by echocardiogram. The diagnosis and treatment are discussed separately. Of note, beta-adrenergic antagonists (ie, beta-blockers) are avoided in cocaine-related cardiovascular disease because they may create unopposed alpha-adrenergic stimulation. (See  <a class="medical medical_review" href="/d/html/4953.html" rel="external">"Clinical manifestations, diagnosis, and management of the cardiovascular complications of cocaine abuse", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/303.html" rel="external">"Cocaine: Acute intoxication", section on 'Cardiovascular complications'</a> and  <a class="medical medical_review" href="/d/html/3454.html" rel="external">"Treatment of acute decompensated heart failure: General considerations"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pneumothorax and pneumomediastinum are also reported in association with cocaine inhalation. (See <a class="local">'Pneumothorax and pneumomediastinum'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic pulmonary complications</strong> – The chronic pulmonary complications of injection cocaine use include foreign body granulomatosis, lung scarring due to repeated pulmonary infections and pulmonary infarction, and pulmonary arterial hypertension (PAH) [<a href="#rid31">31</a>]. (See <a class="local">'Foreign body granulomatosis'</a> above and <a class="local">'Interstitial lung disease'</a> above and <a class="local">'Pulmonary hypertension'</a> above.)</p><p></p><p class="headingAnchor" id="H16"><span class="h2">Opioids</span><span class="headingEndMark"> — </span>Opiates are naturally occurring alkaloids from the poppy plant; the term “opioids” includes natural opiates (eg, <a class="drug drug_general" data-topicid="9788" href="/d/drug information/9788.html" rel="external">morphine</a>, <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a>) and synthetic derivatives that also bind to opioid receptors in the brain (eg, heroin, <a class="drug drug_general" data-topicid="91299" href="/d/drug information/91299.html" rel="external">hydrocodone</a>). Use of heroin (diacetyl morphine) is rising in the United States, and increasingly pure formulations of the drug are available. Most of the direct morbidity and mortality related to opiate use occur after acute intoxication and are due to anaphylaxis, noncardiogenic pulmonary edema, acute respiratory acidosis, and aspiration pneumonitis. (See  <a class="medical medical_review" href="/d/html/300.html" rel="external">"Acute opioid intoxication in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>Massive release of histamine from mast cells and basophils may follow narcotic injection due to an anaphylactoid reaction to the narcotics themselves or to adulterants or contaminants. Shock, bronchospasm, and upper airway edema may ensue [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/392.html" rel="external">"Anaphylaxis: Emergency treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heroin-induced noncardiogenic pulmonary edema usually develops rapidly within the first few hours following injection, but rarely occurs as late as 24 hours. This complication can also occur with other opiates such as <a class="drug drug_general" data-topicid="9291" href="/d/drug information/9291.html" rel="external">codeine</a> and <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, as well as fentanyl-heroin mixtures [<a href="#rid33">33</a>]. Oxygen therapy and noninvasive positive pressure ventilation or intubation with mechanical ventilation may be required. Improvement can occur rapidly, but full resolution generally requires two to three days. (See <a class="local">'Noncardiogenic pulmonary edema'</a> above and  <a class="medical medical_review" href="/d/html/3456.html" rel="external">"Noncardiogenic pulmonary edema"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Diffuse alveolar hemorrhage has been described as a complication of heroin overdose, although it is not known whether the hemorrhage was due to a contaminant in the heroin or a consequence of noncardiogenic pulmonary edema with capillary leak [<a href="#rid34">34</a>]. Contamination of heroin by cocaine or levamisole was thought to be unlikely in the reported patients as the urine cocaine and antineutrophil cytoplasmic antibody (ANCA) tests were negative. (See <a class="local">'Cocaine'</a> above and  <a class="medical medical_review" href="/d/html/303.html" rel="external">"Cocaine: Acute intoxication", section on 'Levamisole'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Narcotics powerfully suppress central respiratory drive. Acute administration may produce hypercapnia, acute respiratory acidosis, and if severe, cardiopulmonary arrest and death. (See  <a class="medical medical_review" href="/d/html/300.html" rel="external">"Acute opioid intoxication in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Narcotics also diminish the level of consciousness and depress the cough reflex. These actions render narcotic users less able to protect the airway and more likely to develop aspiration pneumonitis (due to infection or aspirated gastric contents) and lung abscess. Lower lobe bronchiectasis has been reported among heroin users and may result from prior episodes of aspiration or pulmonary infection [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/d/html/7024.html" rel="external">"Aspiration pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/7030.html" rel="external">"Lung abscess in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a case report, an intravenous heroin user developed respiratory failure due to organizing pneumonia; scattered, nonnecrotizing granulomata and multinucleated giant cells with foreign body particles were also noted [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Methylphenidate and methamphetamine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">Methylphenidate</a> and methamphetamine are sympathomimetic stimulants that are sometimes injected intravenously by PWID. General signs and symptoms of toxicity include restlessness, tachycardia, hypertension, diaphoresis, and confusion. Long-term use of methylphenidate can lead to bullous emphysema.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">Methylphenidate</a> – Intravenous methylphenidate has been associated with the development of hemoptysis, chest pain, and wheezing. One series of 22 patients hospitalized following methylphenidate use reported that 80 percent had one or more of these findings [<a href="#rid37">37</a>]. Excess adrenergic activity and vasospasm may underlie these complications.</p><p></p><p class="bulletIndent1">Habitual intravenous use of <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a> has been associated with the development of panlobar emphysema after one to six years [<a href="#rid18">18,38</a>]. Emphysema primarily involves the lower lobes of the lungs and has a similar radiographic appearance to alpha-1 antitrypsin deficiency. The relative contribution of methylphenidate, foreign body granulomatosis, and concomitant smoking in the genesis of emphysema among these patients is unclear, but one study compared the findings on chest computed tomography (CT) of patients with foreign body granulomatosis who abused intravenous methylphenidate with others who did not [<a href="#rid39">39</a>]. A significantly increased prevalence of lower lobe panacinar emphysema was demonstrated in patients abusing methylphenidate, and was frequently associated with a fine micronodular pattern and ground-glass attenuation. (See <a class="local">'Bullous lung disease and emphysema'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methamphetamine</strong> – Methamphetamine ("speed" or "crank") is a stimulant drug that has similar effects to cocaine. It can be smoked or administered intravenously or intranasally. There are rare case reports of acute noncardiogenic pulmonary edema and pulmonary hypertension following the inhalation of methamphetamine, but complications of intravenous use are not well documented. Cardiogenic pulmonary edema can complicate methamphetamine intoxication, possibly related to fluid resuscitation in the setting of acute hypertension. (See  <a class="medical medical_review" href="/d/html/311.html" rel="external">"Methamphetamine: Acute intoxication", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/d/html/311.html" rel="external">"Methamphetamine: Acute intoxication", section on 'Fluid resuscitation'</a>.)</p><p></p><p>The evaluation and management of acute methamphetamine intoxication are discussed separately. (See  <a class="medical medical_review" href="/d/html/311.html" rel="external">"Methamphetamine: Acute intoxication"</a>.)</p><p class="headingAnchor" id="H1849671960"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115010.html" rel="external">"Society guideline links: Stimulant use disorder and withdrawal"</a>.)</p><p class="headingAnchor" id="H97240033"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary disease associated with IV drug use</strong> – Pulmonary complications associated with intravenous (IV) injection of illicit drugs include pneumonia, septic embolization, foreign body granulomatosis, emphysema, interstitial lung disease, organizing pneumonia, pulmonary vascular disease, pneumothorax, pneumomediastinum, and an increased incidence of fatal asthma. (See <a class="local">'Pulmonary complications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Community-acquired pneumonia</strong> – People who inject drugs (PWID) have a <strong>10-fold</strong> increased risk of community-acquired pneumonia compared with the general population; common causative organisms include <em>Streptococcus pneumoniae</em>, <em>Staphylococcus aureus</em>, <em>Haemophilus influenzae</em>, <em>Klebsiella pneumoniae, </em>and <em>Escherichia coli</em>. In addition, those who develop HIV/AIDS are at risk for opportunistic pulmonary infections (eg, tuberculosis, atypical mycobacteria, <em>Pneumocystis jirovecii</em>, cytomegalovirus). (See <a class="local">'Pneumonia'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Foreign body granulomatosis</strong> – When tablets intended for oral use are pulverized and injected intravenously, the insoluble agents in the tablets (eg, talc, cotton, and cellulose) can be trapped in the pulmonary vasculature, migrate through the vessel walls, and initiate a granulomatous inflammatory response in the perivascular interstitium. This disease process, known as foreign body granulomatosis, can lead to development of progressive interstitial lung disease, emphysema, and pulmonary hypertension. (See <a class="local">'Foreign body granulomatosis'</a> above and  <a class="medical medical_review" href="/d/html/4370.html" rel="external">"Foreign body granulomatosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Emphysema and bullous lung disease</strong> – Emphysema and bullous lung disease may result from concomitant cigarette smoking but are also associated with HIV infection and intravenous injection of <a class="drug drug_general" data-topicid="9623" href="/d/drug information/9623.html" rel="external">methadone</a>, <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a>, and talc-containing drugs. (See <a class="local">'Pulmonary complications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pneumothorax</strong> – Pneumothorax may result from unsuccessful attempts to inject drugs into the central circulation via the subclavian and jugular veins ("pocket shots"). It has also been reported as a complication of septic pulmonary emboli and drug-related bullous disease. (See <a class="local">'Pneumothorax and pneumomediastinum'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary complications of IV cocaine</strong> – Complications of intravenous injection of crack cocaine include noncardiogenic and cardiogenic pulmonary edema, acute and recurrent alveolar hemorrhage, and interstitial lung disease due to foreign body granulomatosis. (See <a class="local">'Cocaine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary complications of IV opioids</strong> – Pulmonary complications related to opioid injection typically occur in the setting of acute intoxication and are due to anaphylaxis, noncardiogenic pulmonary edema, hypoventilation with acute respiratory acidosis, and aspiration pneumonitis. (See <a class="local">'Opioids'</a> above and  <a class="medical medical_review" href="/d/html/300.html" rel="external">"Acute opioid intoxication in adults"</a> and  <a class="medical medical_review" href="/d/html/6504.html" rel="external">"Opioid intoxication in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary complications of IV amphetamines</strong> – Intravenous injection of <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a> has been associated with hemoptysis, chest pain, and wheezing; excess adrenergic activity and vasospasm may underlie these complications. Foreign body granulomatosis and emphysema are complications associated with long-term use. Methamphetamine ("speed" or "crank") is a stimulant drug that has similar effects to cocaine and is rarely associated with noncardiogenic pulmonary edema and pulmonary hypertension. (See <a class="local">'Methylphenidate and methamphetamine'</a> above.)</p><p></p><p class="headingAnchor" id="H1542403923"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jill P Karpel, MD (deceased), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hind CR. Pulmonary complications of intravenous drug misuse. 1. Epidemiology and non-infective complications. Thorax 1990; 45:891.</a></li><li><a class="nounderline abstract_t">Hind CR. Pulmonary complications of intravenous drug misuse. 2. Infective and HIV related complications. Thorax 1990; 45:957.</a></li><li><a class="nounderline abstract_t">Todorović MS, Mitrović S, Aleksandrić B, et al. Association of pulmonary histopathological findings with toxicological findings in forensic autopsies of illicit drug users. Vojnosanit Pregl 2011; 68:639.</a></li><li><a class="nounderline abstract_t">Passarino G, Ciccone G, Siragusa R, et al. Histopathological findings in 851 autopsies of drug addicts, with toxicologic and virologic correlations. Am J Forensic Med Pathol 2005; 26:106.</a></li><li><a class="nounderline abstract_t">Caiaffa WT, Vlahov D, Graham NM, et al. Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users. Am J Respir Crit Care Med 1994; 150:1493.</a></li><li><a class="nounderline abstract_t">Madeddu G, Porqueddu EM, Cambosu F, et al. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era. Infection 2008; 36:231.</a></li><li><a class="nounderline abstract_t">Reichman LB, Felton CP, Edsall JR. Drug dependence, a possible new risk factor for tuberculosis disease. Arch Intern Med 1979; 139:337.</a></li><li><a class="nounderline abstract_t">Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328:521.</a></li><li><a class="nounderline abstract_t">Perlman DC, Salomon N, Perkins MP, et al. Tuberculosis in drug users. Clin Infect Dis 1995; 21:1253.</a></li><li><a class="nounderline abstract_t">Sporer KA, Dorn E. Heroin-related noncardiogenic pulmonary edema : a case series. Chest 2001; 120:1628.</a></li><li><a class="nounderline abstract_t">Sterrett C, Brownfield J, Korn CS, et al. Patterns of presentation in heroin overdose resulting in pulmonary edema. Am J Emerg Med 2003; 21:32.</a></li><li><a class="nounderline abstract_t">Kissner DG, Lawrence WD, Selis JE, Flint A. Crack lung: pulmonary disease caused by cocaine abuse. Am Rev Respir Dis 1987; 136:1250.</a></li><li><a class="nounderline abstract_t">O'Donnell AE, Pappas LS. Pulmonary complications of intravenous drug abuse. Experience at an inner-city hospital. Chest 1988; 94:251.</a></li><li><a class="nounderline abstract_t">Paré JP, Cote G, Fraser RS. Long-term follow-up of drug abusers with intravenous talcosis. Am Rev Respir Dis 1989; 139:233.</a></li><li><a class="nounderline abstract_t">Stern EJ, Frank MS, Schmutz JF, et al. Panlobular pulmonary emphysema caused by i.v. injection of methylphenidate (Ritalin): findings on chest radiographs and CT scans. AJR Am J Roentgenol 1994; 162:555.</a></li><li><a class="nounderline abstract_t">Goldstein DS, Karpel JP, Appel D, Williams MH Jr. Bullous pulmonary damage in users of intravenous drugs. Chest 1986; 89:266.</a></li><li><a class="nounderline abstract_t">Gurney JW, Bates FT. Pulmonary cystic disease: comparison of Pneumocystis carinii pneumatoceles and bullous emphysema due to intravenous drug abuse. Radiology 1989; 173:27.</a></li><li><a class="nounderline abstract_t">Shlomi D, Shitrit D, Bendayan D, et al. Successful lung transplantation for talcosis secondary to intravenous abuse of oral drug. Int J Chron Obstruct Pulmon Dis 2008; 3:327.</a></li><li><a class="nounderline abstract_t">Marchiori E, Lourenço S, Gasparetto TD, et al. Pulmonary talcosis: imaging findings. Lung 2010; 188:165.</a></li><li><a class="nounderline abstract_t">Koslik HJ, Joshua J, Cuevas-Mota J, et al. Prevalence and correlates of obstructive lung disease among people who inject drugs, San Diego, California. Drug Alcohol Depend 2020; 214:108158.</a></li><li><a class="nounderline abstract_t">Chin KM, Channick RN, Rubin LJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 2006; 130:1657.</a></li><li><a class="nounderline abstract_t">Aguado JM, Arjona R, Ugarte P. Septic pulmonary emboli. A rare cause of bilateral pneumothorax in drug abusers. Chest 1990; 98:1302.</a></li><li><a class="nounderline abstract_t">Fiorelli A, Accardo M, Rossi F, Santini M. Spontaneous pneumothorax associated with talc pulmonary granulomatosis after cocaine inhalation. Gen Thorac Cardiovasc Surg 2016; 64:174.</a></li><li><a class="nounderline abstract_t">Alnas M, Altayeh A, Zaman M. Clinical course and outcome of cocaine-induced pneumomediastinum. Am J Med Sci 2010; 339:65.</a></li><li><a class="nounderline abstract_t">Levenson T, Greenberger PA, Donoghue ER, Lifschultz BD. Asthma deaths confounded by substance abuse. An assessment of fatal asthma. Chest 1996; 110:604.</a></li><li class="breakAll">National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on February 28, 2011).</li><li><a class="nounderline abstract_t">Levine M, Iliescu ME, Margellos-Anast H, et al. The effects of cocaine and heroin use on intubation rates and hospital utilization in patients with acute asthma exacerbations. Chest 2005; 128:1951.</a></li><li><a class="nounderline abstract_t">Doshi V, Shenoy S, Ganesh A, et al. Profile of Acute Asthma Exacerbation in Drug Users. Am J Ther 2017; 24:e39.</a></li><li><a class="nounderline abstract_t">Shah SP, Khine M, Anigbogu J, Miller A. Nodular amyloidosis of the lung from intravenous drug abuse: an uncommon cause of multiple pulmonary nodules. South Med J 1998; 91:402.</a></li><li><a class="nounderline abstract_t">Bailey ME, Fraire AE, Greenberg SD, et al. Pulmonary histopathology in cocaine abusers. Hum Pathol 1994; 25:203.</a></li><li><a class="nounderline abstract_t">Yakel DL Jr, Eisenberg MJ. Pulmonary artery hypertension in chronic intravenous cocaine users. Am Heart J 1995; 130:398.</a></li><li><a class="nounderline abstract_t">Edston E, van Hage-Hamsten M. Anaphylactoid shock--a common cause of death in heroin addicts? Allergy 1997; 52:950.</a></li><li><a class="nounderline abstract_t">Algren DA, Monteilh CP, Punja M, et al. Fentanyl-associated fatalities among illicit drug users in Wayne County, Michigan (July 2005-May 2006). J Med Toxicol 2013; 9:106.</a></li><li><a class="nounderline abstract_t">Riccardello GJ Jr, Maldjian PD. Pulmonary hemorrhage in acute heroin overdose: a report of two cases. Emerg Radiol 2017; 24:709.</a></li><li><a class="nounderline abstract_t">Banner AS, Rodriguez J, Sunderrajan EV, et al. Bronchiectasis: a cause of pulmonary symptoms in heroin addicts. Respiration 1979; 37:232.</a></li><li><a class="nounderline abstract_t">Bishay A, Amchentsev A, Saleh A, et al. A hitherto unreported pulmonary complication in an IV heroin user. Chest 2008; 133:549.</a></li><li><a class="nounderline abstract_t">Parran TV Jr, Jasinski DR. Intravenous methylphenidate abuse. Prototype for prescription drug abuse. Arch Intern Med 1991; 151:781.</a></li><li><a class="nounderline abstract_t">Sherman CB, Hudson LD, Pierson DJ. Severe precocious emphysema in intravenous methylphenidate (Ritalin) abusers. Chest 1987; 92:1085.</a></li><li><a class="nounderline abstract_t">Ward S, Heyneman LE, Reittner P, et al. Talcosis associated with IV abuse of oral medications: CT findings. AJR Am J Roentgenol 2000; 174:789.</a></li></ol></div><div id="topicVersionRevision">Topic 4337 Version 19.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2256022" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Pulmonary complications of intravenous drug misuse. 1. Epidemiology and non-infective complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2281430" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pulmonary complications of intravenous drug misuse. 2. Infective and HIV related complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21991785" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Association of pulmonary histopathological findings with toxicological findings in forensic autopsies of illicit drug users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894841" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Histopathological findings in 851 autopsies of drug addicts, with toxicologic and virologic correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7952605" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Drug smoking, Pneumocystis carinii pneumonia, and immunosuppression increase risk of bacterial pneumonia in human immunodeficiency virus-seropositive injection drug users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18463787" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/426578" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Drug dependence, a possible new risk factor for tuberculosis disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8381207" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The emergence of drug-resistant tuberculosis in New York City.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8589151" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Tuberculosis in drug users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11713145" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Heroin-related noncardiogenic pulmonary edema : a case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12563576" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Patterns of presentation in heroin overdose resulting in pulmonary edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3674585" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Crack lung: pulmonary disease caused by cocaine abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3396399" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pulmonary complications of intravenous drug abuse. Experience at an inner-city hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2912344" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Long-term follow-up of drug abusers with intravenous talcosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8109495" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Panlobular pulmonary emphysema caused by i.v. injection of methylphenidate (Ritalin): findings on chest radiographs and CT scans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3943387" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Bullous pulmonary damage in users of intravenous drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2789412" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pulmonary cystic disease: comparison of Pneumocystis carinii pneumatoceles and bullous emphysema due to intravenous drug abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18686743" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Successful lung transplantation for talcosis secondary to intravenous abuse of oral drug.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20155272" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pulmonary talcosis: imaging findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32652379" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Prevalence and correlates of obstructive lung disease among people who inject drugs, San Diego, California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166979" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2225993" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Septic pulmonary emboli. A rare cause of bilateral pneumothorax in drug abusers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24942102" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Spontaneous pneumothorax associated with talc pulmonary granulomatosis after cocaine inhalation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20057278" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical course and outcome of cocaine-induced pneumomediastinum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8797399" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Asthma deaths confounded by substance abuse. An assessment of fatal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8797399" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Asthma deaths confounded by substance abuse. An assessment of fatal asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16236840" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The effects of cocaine and heroin use on intubation rates and hospital utilization in patients with acute asthma exacerbations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25310021" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Profile of Acute Asthma Exacerbation in Drug Users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9563439" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Nodular amyloidosis of the lung from intravenous drug abuse: an uncommon cause of multiple pulmonary nodules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8119721" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pulmonary histopathology in cocaine abusers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7631626" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pulmonary artery hypertension in chronic intravenous cocaine users.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9298181" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anaphylactoid shock--a common cause of death in heroin addicts?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23359211" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fentanyl-associated fatalities among illicit drug users in Wayne County, Michigan (July 2005-May 2006).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28674923" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pulmonary hemorrhage in acute heroin overdose: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/472503" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bronchiectasis: a cause of pulmonary symptoms in heroin addicts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18252922" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A hitherto unreported pulmonary complication in an IV heroin user.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1849397" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intravenous methylphenidate abuse. Prototype for prescription drug abuse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3677815" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Severe precocious emphysema in intravenous methylphenidate (Ritalin) abusers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10701626" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Talcosis associated with IV abuse of oral medications: CT findings.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
